How do you pay?

How to pay the least

From

$4 for 30 tablets, any strength

Generic atenolol at Walmart

  1. Ask your prescriber to send the prescription to your nearest Walmart. Or ask the store’s pharmacy to transfer it from your pharmacy.Find the nearest store 
  2. Ask for generic atenolol.See Walmart’s price list 

Rather have it mailed? From $8 a month from Rx Outreach, by mail. Make a free account, then have your prescription sent there.

Open Rx Outreach 

A regular generic has the same active ingredient as Tenormin, and the FDA requires it to work the same way.

Compare every option

Question
Brand nameTenormin
Authorized genericatenolol
Regular genericatenolol
What you’d pay
At least$380for 30 tablets; pharmacies pay this
Not soldThere isn’t one
From$4for 30 tablets at Walmart
Same as Tenormin?
The original
–
Same active ingredientFillers and dyes can differ

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Tenormin’s maker. Ask the pharmacy for Tenormin’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Tenormin itself, from the same company, sold without the brand name, and usually for less. A regular generic is sold, with the same active ingredient: ask the pharmacy for its price.

See the regular generic →

Regular genericWhere to buy it

Pharmacies’ own cash prices for generic atenolol, lowest first.

Pick up in storeDelivered

From each pharmacy’s own site, read November 2, 2026. Confirm the price before you fill.

About these prices

Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.

Regular genericWho makes it

8 companies sell a generic of Tenormin that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.

  • Aurobindo PharmaAll 3 strengths

    Product page on aurobindousa.com

    How it looks, what’s in it, NDCs

    25 mg White to Off-white, round, 6 mm, marked “D / 21”

    PackageNDC
    Bottle of 10065862-168-01
    Bottle of 100065862-168-99

    50 mg White to Off-white, round, 7 mm, marked “D / 22”

    PackageNDC
    Bottle of 10065862-169-01
    Bottle of 100065862-169-99

    100 mg White to Off-white, round, 9 mm, marked “D / 23”

    PackageNDC
    Bottle of 10065862-170-01
    Bottle of 100065862-170-99

    Inactive ingredients: sodium starch glycolate type a potato, crospovidone (120 .mu.m), povidone k90, microcrystalline cellulose, silicon dioxide, magnesium stearate

    FDA label

  • Ipca LaboratoriesAll 3 strengths

    Product page on unichemusa.com

    How it looks, what’s in it, NDCs

    25 mg White, round, 6 mm, marked “RE / 19”

    PackageNDC
    Bottle of 1083980-022-97
    Bottle of 10083980-022-01
    Bottle of 100083980-022-10

    50 mg White, round, 7 mm, marked “RE / 20”

    PackageNDC
    Bottle of 1083980-023-97
    Bottle of 10083980-023-01
    Bottle of 100083980-023-10

    100 mg White, round, 9 mm, marked “RE / 21”

    PackageNDC
    Bottle of 1083980-024-97
    Bottle of 10083980-024-01
    Bottle of 100083980-024-10

    Inactive ingredients: magnesium carbonate, magnesium stearate, sodium lauryl sulfate, sodium starch glycolate type a potato, starch, corn, silicon dioxide

    FDA label

  • Mylan InstitutionalAll 3 strengths
    How it looks, what’s in it, NDCs

    25 mg White to off-white, round, 6 mm, marked “M / A2”

    PackageNDC
    Carton of 10051079-759-20

    50 mg White, round, 7 mm, marked “M / 231”

    PackageNDC
    Carton of 10051079-684-20

    100 mg White, round, 9 mm, marked “M / 757”

    PackageNDC
    Carton of 10051079-685-20

    Inactive ingredients: silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate type a potato

    FDA label

  • Mylan PharmaceuticalsAll 3 strengths
    How it looks, what’s in it, NDCs

    25 mg White to off-white, round, 6 mm, marked “M / A2”

    PackageNDC
    Bottle of 1000378-0218-01
    Bottle of 10000378-0218-10

    50 mg White, round, 7 mm, marked “M / 231”

    PackageNDC
    Bottle of 1000378-0231-01
    Bottle of 10000378-0231-10

    100 mg White, round, 9 mm, marked “M / 757”

    PackageNDC
    Bottle of 1000378-0757-01
    Bottle of 10000378-0757-10

    Inactive ingredients: silicon dioxide, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate type a potato

    FDA label

  • Rising Pharma HoldingsAll 3 strengths

    Made by Unique Pharmaceutical Laboratories

    How it looks, what’s in it, NDCs

    25 mg White, round, 6 mm, marked “ATN / 25”

    PackageNDC
    Bottle of 10064980-437-01
    Bottle of 100064980-437-10

    50 mg White, round, 8 mm, marked “ATN / 50”

    PackageNDC
    Bottle of 10064980-438-01
    Bottle of 100064980-438-10

    100 mg White, round, 10 mm, marked “ATN / 100”

    PackageNDC
    Bottle of 10064980-439-01
    Bottle of 100064980-439-10

    Inactive ingredients: magnesium stearate, cellulose, microcrystalline, povidone, sodium starch glycolate type a potato, hypromelloses, titanium dioxide, glycerin

    FDA label

  • Teva PharmaceuticalsAll 3 strengths

    Product page on tevausa.com

    How it looks, what’s in it, NDCs

    25 mg White to off-white marble, round, 6 mm, marked “787 / TEVA”

    PackageNDC
    Bottle of 1000093-0787-01
    Bottle of 10000093-0787-10

    50 mg White to off-white marble, round, 7 mm, marked “93 / 752 / TEVA”

    PackageNDC
    Bottle of 1000093-0752-01
    Bottle of 10000093-0752-10

    100 mg White to off-white marble, round, 9 mm, marked “753 / TEVA”

    PackageNDC
    Bottle of 1000093-0753-01
    Bottle of 5000093-0753-05

    Inactive ingredients: magnesium stearate, cellulose, microcrystalline, povidone k30, sodium starch glycolate type a potato

    FDA label

  • Unichem PharmaceuticalsAll 3 strengths

    Product page on unichemusa.com

    How it looks, what’s in it, NDCs

    25 mg White to off white, capsule, 7 mm, marked “U / 22”

    PackageNDC
    Bottle of 10029300-410-01
    Bottle of 50029300-410-05
    Bottle of 100029300-410-10

    50 mg White to off white, round, 7 mm, marked “U / 2 / 1”

    PackageNDC
    Bottle of 10029300-411-01
    Bottle of 50029300-411-05
    Bottle of 100029300-411-10

    100 mg White to off white, round, 9 mm, marked “U / 20”

    PackageNDC
    Bottle of 10029300-412-01
    Bottle of 50029300-412-05
    Bottle of 100029300-412-10

    Inactive ingredients: magnesium stearate, microcrystalline cellulose, povidone k30, silicon dioxide, sodium starch glycolate type a potato

    FDA label

  • Zydus LifesciencesAll 3 strengths
    How it looks, what’s in it, NDCs

    25 mg WHITE TO OFF- WHITE, round, 6 mm, marked “Z / 65”

    PackageNDC
    Bottle of 9068382-022-16
    Bottle of 10068382-022-01
    Bottle of 100068382-022-10
    Bottle of 500068382-022-40
    Bottle of 1000068382-022-24

    50 mg WHITE TO OFF- WHITE, round, 8 mm, marked “Z / 66”

    PackageNDC
    Bottle of 9068382-023-16
    Bottle of 10068382-023-01
    Bottle of 100068382-023-10
    Bottle of 200068382-023-02
    Bottle of 500068382-023-40
    Bottle of 1000068382-023-24

    100 mg WHITE TO OFF- WHITE, round, 10 mm, marked “Z / 67”

    PackageNDC
    Bottle of 9068382-024-16
    Bottle of 10068382-024-01
    Bottle of 100068382-024-10
    Bottle of 500068382-024-40

    Inactive ingredients: anhydrous citric acid, croscarmellose sodium, magnesium stearate, silicon dioxide, povidone, cellulose, microcrystalline

    FDA label

Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.

What to say at the pharmacy

“Before you fill my Tenormin, can you tell me what I’d pay for the brand and for a generic?”

Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.

What it’s used for

What the FDA label says

Hypertension

TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

TENORMIN may be administered with other antihypertensive agents.

Angina Pectoris Due to Coronary Atherosclerosis

TENORMIN is indicated for the long-term management of patients with angina pectoris.

Acute Myocardial Infarction

TENORMIN is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS.) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit.

Source: the FDA label for Tenormin (Upsher-Smith Laboratories, LLC), September 18, 2025. Full label on DailyMed 

Good to know